JETEMA, Co., Ltd. (216080.KQ)
KRW 15130.0
(-2.64%)
KRW 15130.0
(-2.64%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 26.58 Billion KRW | 29.88% |
| 2022 | 20.46 Billion KRW | 44.69% |
| 2021 | 14.14 Billion KRW | 76.8% |
| 2020 | 8 Billion KRW | 49.6% |
| 2019 | 5.34 Billion KRW | 5.99% |
| 2018 | 5.04 Billion KRW | 98.89% |
| 2017 | 2.53 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 10.06 Billion KRW | 13.77% |
| 2024 Q1 | 8.85 Billion KRW | 23.98% |
| 2023 Q1 | 5.86 Billion KRW | -9.02% |
| 2023 Q3 | 6.76 Billion KRW | -0.66% |
| 2023 Q2 | 6.81 Billion KRW | 16.07% |
| 2023 FY | 26.58 Billion KRW | 29.88% |
| 2023 Q4 | 7.13 Billion KRW | 5.53% |
| 2022 Q2 | 5.29 Billion KRW | 37.13% |
| 2022 Q1 | 3.85 Billion KRW | -12.1% |
| 2022 Q3 | 5.78 Billion KRW | 9.31% |
| 2022 FY | 20.46 Billion KRW | 44.69% |
| 2022 Q4 | 6.44 Billion KRW | 11.51% |
| 2021 Q3 | 2.18 Billion KRW | -46.46% |
| 2021 Q4 | 4.38 Billion KRW | 101.27% |
| 2021 Q1 | 3.5 Billion KRW | -5.44% |
| 2021 FY | 14.14 Billion KRW | 76.8% |
| 2021 Q2 | 4.07 Billion KRW | 16.32% |
| 2020 Q3 | 2.09 Billion KRW | 71.19% |
| 2020 Q1 | 1.71 Billion KRW | 66.91% |
| 2020 FY | 8 Billion KRW | 49.6% |
| 2020 Q4 | 3.7 Billion KRW | 76.62% |
| 2020 Q2 | 1.22 Billion KRW | -28.68% |
| 2019 Q3 | 1.74 Billion KRW | 0.0% |
| 2019 FY | 5.34 Billion KRW | 5.99% |
| 2019 Q4 | 1.02 Billion KRW | -41.07% |
| 2019 Q1 | 1.18 Billion KRW | 0.0% |
| 2018 Q1 | 1.01 Billion KRW | 0.0% |
| 2018 FY | 5.04 Billion KRW | 98.89% |
| 2017 FY | 2.53 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 542.113% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | -482.827% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 53.081% |
| Bioneer Corporation | 199.25 Billion KRW | 86.659% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | -1100.935% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | 33.85% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | -1724.425% |
| Helixmith Co., Ltd | 2.12 Billion KRW | -1152.773% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 89.584% |
| Medy-Tox Inc. | 128.16 Billion KRW | 79.259% |
| Peptron, Inc. | 1.14 Billion KRW | -2230.568% |
| Amicogen, Inc. | 51.51 Billion KRW | 48.397% |
| Genexine, Inc. | 387.48 Million KRW | -6760.133% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | -297.086% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | -49.36% |
| ALTEOGEN Inc. | 31.19 Billion KRW | 14.797% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 85.415% |
| SillaJen, Inc. | 1.45 Billion KRW | -1724.754% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | -84.311% |
| Genomictree Inc. | -1.03 Billion KRW | 2659.42% |
| MedPacto, Inc. | -1.83 Billion KRW | 1550.455% |
| D&D Pharmatech | 18.67 Billion KRW | -42.324% |
| EASY BIO,Inc. | 50.88 Billion KRW | 47.762% |
| GI Innovation, Inc. | 1.98 Billion KRW | -1236.165% |